Published on : Mar 03, 2017
ALBANY, NY, March 03, 2017: The report is a thorough study of the products that are available in the market for the treatment Parkinson’s disease, evaluates the promises made by pipeline products, and presents several information in the form of heat map for the buyers to gauge a clear picture of the market in its current scenario.
The report observes that Parkinson’s disease is a chronic neurodegenerative disease, which is characterized by its progressiveness in terms of loss of muscular control, rigidity, resting tumor, and akinesia and postural reflex impairment. Since Parkinson’s diseases are an age-related disorder, with the symptoms typically appearing in patients aged over six years, rising geriatric population across the world is the primary driver of this market. The National Institute of Aging estimates that the population of people aged over 65 years will increase up to 1.5 billion.
This makes for a vast potential patient-base over the course of next few years. Patent expiries of several key products in the next few years, including Stalevo, Azilect, and Neupro are also expected to enable new players to make their presence felt over the global market. The new entrants in particular are anticipated to emerge as drug developers while focusing on offering easier methods of administration and continuous relief. For instance, four new levodopa formulations will enter market by 2021, with each of them designed to enhance off-episodes in advanced Parkinson’s disease patients by providing consistent drug administration.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=970727
As there is no absolute cure currently available for Parkinson’s diseases, significant efforts are being made to develop new treatments and meet the need. Some of the products analyzed by the report are catechol-O-methyltransferase inhibitors, levodopa-plus-carbidopa-based treatments, monoamine oxidase-B inhibitors, dopamine agonists, and other alternative treatments. The report also finds that the difference in these products lie in their mechanisms of action, which must be completely understood by the vendors who are eyeing a strong position in this novel drug market. With a tabular heat map framework, the report provides illustrious summary of the clinical characteristics. It also notes all the safety and efficacy endpoints of these trials, besides providing color-coded manner and visually accessible study in order to maximize ease of use.
Several key questions answered by the report, including the clinical characteristics of the recently approved therapies and the key unmet needs in the indications which are clinical safe and meet the efficacy parameters. It also tries to evaluate how the late-stage molecules will fare in the market for levodopa therapies, and the benefits from other disease-modifying therapies in the future.
Some of the key companies currently operating in this market are Novartis, Lundbeck, UCB, Teva, and Roche.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org